If you have been reading about prohibited list and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-10-02. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
tissue-specific gene expression Gene function and expression which is restricted to a particular tissue or cell type. Tissue-specific expression is usually the result of an enhancer which is activated only in the proper cell type.
=== Physical features === LS is recognized as being part of a spectrum of conditions that affect the Hypothalamic–pituitary–somatotropic axis and cause significant derangements in human growth, development, and metabolism. Along this spectrum of conditions, individuals with LS and growth hormone deficiency display short stature, while individuals with acromegaly and gigantism result in the opposite phenotype of tall stature. In addition to short stature, other characteristic physical symptoms of LS include: prominent forehead, depressed nasal bridge, underdevelopment of mandible, truncal obesity, and micropenis in males. Left untreated, the average height attained by individuals with LS are approximately 4–4.5 feet (1.2–1.4 m) in women/men respectively. Additional physical features include delayed bone age, hypogonadism, blue sclera, high-pitched voice, acrohypoplasia, sparse hair growth, and crowded teeth. The breasts of females reach normal size, and in some are large in relation to body size. It has been suggested that hyperprolactinemia may contribute to the enlarged breast size. Seizures are frequently seen secondary to hypoglycemia. Some genetic variations decrease intellectual capacity. Laron syndrome patients also do not develop acne, except temporarily during treatment with IGF-1 (if performed).
The earliest known description of the disease was in 1841 by the American physician Charles Oscar Waters. The condition was described in further detail in 1872 by the American physician George Huntington. The genetic basis was discovered in 1993 by an international collaborative effort led by the Hereditary Disease Foundation. Research and support organizations began forming in the late 1960s to increase public awareness, provide support for the afflicted and their families, and promote research. Research directions include determining the exact mechanism of the disease, improving animal models to aid with research, testing of medications and their delivery to treat symptoms or slow the progression of the disease, and studying procedures such as stem-cell therapy with the goal of replacing damaged or lost neurons.
Sources: en.wikipedia.org
In the United States the press began using the terms "Jewish National Home", "Jewish State", "Jewish republic" and "Jewish Commonwealth" interchangeably. Treaty expert David Hunter Miller, who was at the conference and subsequently compiled a 22 volume compendium of documents, provides a report of the Intelligence Section of the American Delegation to the Paris Peace Conference of 1919 which recommended that "there be established a separate state in Palestine," and that "it will be the policy of the League of Nations to recognize Palestine as a Jewish state, as soon as it is a Jewish state in fact." The report further advised that an independent Palestinian state under a British League of Nations mandate be created. Jewish settlement would be allowed and encouraged in this state and this state's holy sites would be under the control of the League of Nations. Indeed, the Inquiry spoke positively about the possibility of a Jewish state eventually being created in Palestine if the necessary demographics for this were to exist. Historian Matthew Jacobs later wrote that the US approach was hampered by the "general absence of specialist knowledge about the region" and that "like much of the Inquiry's work on the Middle East, the reports on Palestine were deeply flawed" and "presupposed a particular outcome of the conflict". He quotes Miller, writing about one report on the history and impact of Zionism, "absolutely inadequate from any standpoint and must be regarded as nothing more than material for a future report".
Tui na (推拿) is a form of massage, based on the assumptions of TCM, from which shiatsu is thought to have evolved. Techniques employed may include thumb presses, rubbing, percussion, and assisted stretching.
By the Palaiologan period, the dominance of strict compositional rules lessened and John Koukouzeles led a new school favouring a more ornamental "kalophonic" style which deeply informed post-empire Neo-Byzantine music. Secular music, often state-sponsored, was ubiquitous in daily life and featured in a variety of ceremonies, festivals, and theatre. Secular vocal music was rarely notated, and extant manuscripts date much later, suggesting the tradition was passed through oral tradition and likely improvised. Prohibited for liturgical use, a wide variety of Byzantine instruments flourished in secular contexts, although no notated instrumental music survives. It is uncertain to what extent instrumentalists improvised or if they doubled vocalists monophonically or heterophonically. Among the best known instruments are the hydraulic organ, used for circus and imperial court events; the ancient Greek-descended aulos, a wind instrument; the tambouras, a plucked string instrument; and mostly popularly, the Byzantine lyra. Prominent genres included acclamation chants of laudation or salutation; the celebratory Acritic songs; symposia instrumental banquets, based on ancient symposiums; and dance music.
Sources: en.wikipedia.org
=== ECG/EKG === ECGs of patients with cardiac amyloidosis usually show a low voltage in the limb leads, with an unusual extreme right axis. There is usually a normal P-wave, however, it can be slightly prolonged. For patients with light-chain amyloidosis, the QRS complex pattern is skewed, with poor R-waves of the chest leads. In TTR amyloidosis, there is often a discordance between wall thickness suggested by EKG and actual wall thickness, with lower voltages on EKG underestimating wall thickness. Holter monitors can be used to identify asymptomatic arrhythmias. EKG changes may be present, showing low voltage and conduction abnormalities like atrioventricular block or sinus node dysfunction. Atrial fibrillation (AF) is observed in up to 70% of patients at the time of diagnosis, and patients typically have controlled ventricular rates caused by concomitant conduction system disease.
=== Availability === Nemonapride is marketed only in Japan and China. It was also under development for use in other countries, such as France, but development in other countries was discontinued. There are no further plans for nemonapride to be developed for use in the United States, the United Kingdom, or Europe.
Using Mendeleev's nomenclature for unnamed and undiscovered elements, copernicium should be known as eka-mercury. In 1979, IUPAC published recommendations according to which the element was to be called ununbium (with the corresponding symbol of Uub), a systematic element name as a placeholder, until the element was discovered (and the discovery then confirmed) and a permanent name was decided on. Although widely used in the chemical community on all levels, from chemistry classrooms to advanced textbooks, the recommendations were mostly ignored among scientists in the field, who either called it "element 112", with the symbol of E112, (112), or even simply 112. After acknowledging the GSI team's discovery, the IUPAC asked them to suggest a permanent name for element 112. On 14 July 2009, they proposed copernicium with the element symbol Cp, after Nicolaus Copernicus "to honor an outstanding scientist, who changed our view of the world". During the standard six-month discussion period among the scientific community about the naming, it was pointed out that the symbol Cp was previously associated with the name cassiopeium (cassiopium), now known as lutetium (Lu). Moreover, Cp is frequently used today to mean the cyclopentadienyl ligand (C5H5). Primarily because cassiopeium (Cp) was (until 1949) accepted by IUPAC as an alternative allowed name for lutetium, the IUPAC disallowed the use of Cp as a future symbol, prompting the GSI team to put forward the symbol Cn as an alternative.
Maui Mallard in Cold Shadow – originally released as Donald in Maui Mallard (Japanese: Donald Duck no Maui Mallard (ドナルドダックのマウイマラード)) – is a platforming video game developed and published by Disney Interactive. The game was released in Europe in November 1995, and in Brazil in spring 1997 for the Sega Mega Drive. It was also ported by Eurocom Entertainment Software to the SNES and released in North America in January 1997, in Europe mostly in autumn 1996 (although the SNES version was released in Germany at the end of 1995), and in Japan on December 20, 1996. A Microsoft Windows port was released in North America in November 1996. It was ported one last time to the Game Boy by Bonsai Entertainment Corp., released in North America in August 1998. The game stars Donald Duck in a metafictional role as duck detective Maui Mallard (a spoof of 1980s Hawaii-based TV detective, Magnum P.I. in name and appearance), who adopts the name "Cold Shadow" when he dresses up in ninja garb. In the North American versions of the game, all Donald Duck references are absent, and the protagonist is instead referred to as "Maui Mallard," as, according to composer Patrick Collins, the marketing team felt Donald Duck wasn't cool in the United States. Although the end of the game informed the player to look forward to Maui's next adventure, the planned sequel was cancelled. The game was rereleased on the Steam and GOG digital storefronts on May 17, 2019.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.